Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Troglitazone is an anti-diabetic agent that improves hyperglycemia by reducing peripheral insulin resistance in type II diabetic patients. Troglitazone has been shown to cause growth inhibition of various normal and cancerous cells. However,the molecular mechanism by which troglitazone affects the growth of these cancer cells remains unclear. Here, we report that troglitazone treatment of Hep 3B human hepatocellular carcinoma cells resulted in dose-dependent growth inhibition. Analysis of cell cycle distribution by flow cytometry showed that the number of apoptotic cells was increased in a dose-dependent manner in response to troglitazone treatment. cDNA microarray analysis showed a number of differentially expressed genes in response to troglitazone. Among the upregulated genes, hypoxia-inducible factor 1 (HIF-1)-responsive RTP801 was induced in a dose-dependent manner. We also observed HIF-1 accumulation by immnocytochemistry after troglitazone treatment. These results strongly suggest that RTP801 might be involved in troglitazone-induced apoptosis in Hep 3B cells.
Abstract
Troglitazone is an anti-diabetic agent that improves hyperglycemia by reducing peripheral insulin resistance in type II diabetic patients. Troglitazone has been shown to cause growth inhibition of various normal and cancerous cells. However,the molecular mechanism by which troglitazone affects the growth of these cancer cells remains unclear. Here, we report that troglitazone treatment of Hep 3B human hepatocellular carcinoma cells resulted in dose-dependent growth inhibition. Analysis of cell cycle distribution by flow cytometry showed that the number of apoptotic cells was increased in a dose-dependent manner in response to troglitazone treatment. cDNA microarray analysis showed a number of differentially expressed genes in response to troglitazone. Among the upregulated genes, hypoxia-inducible factor 1 (HIF-1)-responsive RTP801 was induced in a dose-dependent manner. We also observed HIF-1 accumulation by immnocytochemistry after troglitazone treatment. These results strongly suggest that RTP801 might be involved in troglitazone-induced apoptosis in Hep 3B cells.
참고문헌 (17)
- Koga, H., "Involvement of p21(WAF1", Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines, 2001, pp.33, 1087~1097
- Yoshizawa, K., "Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines", Cancer, 95, pp.2243~2251 (2002)
- Bae, M. A., "Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines", Toxicol. Lett., 139, pp.67~75 (2003)
- Weng, J. R., "Beyond peroxisome proliferatoractivated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones", Endocr. Relat. Cancer, 13, pp.401~413 (2006)
- Shoshani, T., "Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis", Mol. Cell Biol., 22, pp.2283~2293 (2002)
- Jae-RyongKim, "Identification of amyloid β-peptide responsive genes by cDNA microarray technology: Involvement of RTP801 in amyloid β-peptide toxicity", Experimental and Molecular Medicine, 35(5), pp.403~411 (2003), 생화학분자생물학회
- Schwarzer, R., "REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase", Oncogene, 24, pp.1138~1149 (2005)
- Yu, J., "Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo", Hepatology, 43, pp.134~143 (2006)
- Park, B. C., "Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells", J. Pharmacol. Sci., 111, pp.1~12 (2009)
- Carroll, C. W., "The Doc1 subunit is a processivity factor for the anaphase-promoting complex", Nat. Cell Biol., 4, pp.880~887 (2002)
- Ma, S., "The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB", Mol. Cancer Res., 1, pp.376~384 (2003)
- Ellisen, L. W., "REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species", Mol. Cell, 10, pp.995~1005 (2002)
- Narayanan, P. K., "Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment", Cytometry A., 52, pp.28~35 (2003)
- YoungKwanSung, "Growth promotion of HepG2 hepatoma cells by antisensemediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling", Experimental and Molecular Medicine, 35(4), pp.257~262 (2003), 생화학분자생물학회
- Young Kwan Sung, "Blocking Endogenous Glypican-3 Expression Releases Hep 3B Cells from G1 Arrest", 분자와 세포, 15(3), pp.356~360 (2003), 한국분자세포생물학회
- Moon Kyu Kim, "Gene Expression Profile Analysis in Human Hepatocellular Carcinoma by cDNA Microarray", 분자와 세포, 14(3), pp.382~387 (2002), 한국분자세포생물학회
- Shin, H., "Identification of transcriptional targets of Wnt", beta-catenin signaling in dermal papilla cells of human scalp hair follicles: EP2 is a novel transcriptional target of Wnt3a, 2010, pp.58, 91~96